logo
Drinks that make you chill - do they really do what it says on the tin?

Drinks that make you chill - do they really do what it says on the tin?

Yahoo9 hours ago
Calm in a can. Relaxation after a few sips.
That's what some drinks companies are promising with beverages formulated specifically to help you chill out.
Lucy and Serena swear by them. They're good friends who, like many, are juggling careers, the chaos of having small children, trying to stay fit, and everything else in between.
"These drinks aren't going to get rid of all my worries and anxieties," Serena says, "but if they give me a little boost - then I'll take it."
Lucy finds them really useful too, especially when she's feeling a bit overwhelmed.
"If I get that low-level panic, then with a drink of Trip or something like it, I can bring it back round."
But after an advert by one of the industry's best-known brands was banned for suggesting its drinks helped with stress and anxiety, there have been questions about whether drinks of this kind are quite as effective as they make out.
BBC News has spoken to nutritionists and dietitians who are sceptical the small amounts of supplements the drinks contain could really bring about that sense of zen.
One psychologist has suggested that we might actually "create our own calm" when we set aside time for ourselves with something that feels like a treat.
The "functional beverage" market - that's drinks with additional health benefits - is booming, with British supermarkets seeing sales jump by 24.5% in the last 12 months, according to one market research firm. Almost 30% of UK households now buy these functional drinks, Worldpanel by Numerator says.
So, what's actually in them that's supposed to help you feel more mellow or give your health a boost? Well, that's where things can get complicated, as each brand takes a different approach.
Along with Trip's Mindful Blend, other companies like Rheal, Grass&Co, Goodrays and supermarket own-brands, advertise that their drinks contain supplements including:
Lion's Mane extract – a type of mushroom found in east Asian countries
L-theanine – an amino acid found primarily in green and black tea
Ashwagandha – a herb cultivated in areas of Asia, Africa, and Europe
Magnesium – a mineral the human body needs to function properly
These supplements are all commonly found in many health and wellbeing products and are associated with enhancing mood, boosting energy, supporting cognition, and helping with stress.
But how robust is the evidence for that? It's tricky because there are many studies of varying credibility each suggesting different levels of efficacy.
Trip's advert, which suggested its ingredients were stress and anxiety busters, breached the Advertising Standards Agency's (ASA) code, with the ASA ruling that Trip's claims their drinks could "prevent, treat or cure disease" were a step too far.
Trip told BBC News the ruling related to "a single page on the website" and it has made the "changes requested". It says it's confident it's ingredients permit the use of the word "calm" which is "widely and lawfully used by many brands".
Dietitian Reema Patel is concerned the amount of supplement in these drinks may not give consumers the emotional balance, feelings of calm, or stress relief that is advertised across the industry. She highlights a growing body of evidence around the funghi Lion's Mane, but says there are no conclusive findings about whether it can have any impact - as yet.
"The research is still very much in its infancy," she says. "In one of the more advanced clinical trials, a small number of participants were given 1800mg - that's at least four times more than what is in some of these drinks."
Studies suggest women are more likely to consume these kinds of supplements, but they're not always front and centre in the research.
The lack of research that includes female participants is partly down to menstrual cycles and fluctuating hormones, making it more "complicated to track", Ms Patel explains.
But these drinks can make a good alternative to drinking alcohol she says, and she has clients who have made the switch from having a wine or a gin and tonic every night to opening a can of one of these drinks to help them unwind.
"I think you can take a lot of the claims with a pinch of salt, but they are definitely giving people that other option."
Dr Sinead Roberts, a performance nutritionist, says supplements can make a difference, but they tend to work for certain groups of people in specific circumstances - such as high-performing athletes who want that extra edge, or people who are deficient in a certain nutrient - not necessarily for the general population.
If you enjoy the taste, "crack on", Dr Roberts says, but if you want to reduce stress and anxiety you're probably best saving your £2 or £3 and putting it towards a "therapy session or a massage at the end of the month".
"A trace of Lion's Mane or Ashgawanda in a fizzy drink is not going to make any difference," she adds.
Emily May, 25, first discovered these drinks at Glastonbury a couple of years ago. She's not overly bothered about trying to reach a state of zen through them - she just likes the taste.
"I'm ADHD," Emily says, "so I would definitely need a lot more than one of those drinks to calm me down."
There is a fine line between advertising that a product will give you a feeling of calm and quiet, and claiming these kinds of drinks will help with mental health problems.
Psychologist Natasha Tiwari says mental health and well-being are "increasingly conflated" in the wellness sector, creating a "toxic mix".
There can be a positive - yet temporary - change in mood and consumers might feel a buzz, she says, not because of the ingredients necessarily, but because "everything around the experience of the product is real".
"So you've bought a drink which, let's say, is a little bit pricier than the alternatives in the market. Therefore you make a commitment to sit down quietly and enjoy it nicely," she says. "You look at the branding - which is lovely and calming - you're processing your environment in the moment, and then actually what you're experiencing truly is a calm moment in your otherwise busy day. That's not fake."
And it's that little window of peace that Lucy and Serena yearn for - and for a few minutes a fizzy drink in a can gives them that, whether the science really agrees, or not.
BBC News contacted all the brands mentioned in this article. Grass&Co told us it's their mission "to deliver high-strength natural adaptogen and vitamin-packed blends formulated by experts... which are supported by approved health claims."
More Weekend picks
Sleep, exercise, hydrate - do we really need to stick to recommended daily doses?
People say cola and fries are helping their migraines - but there's a twist
'WeightWatchers set me up to fail' - Why diet industry is losing to jabs like Ozempic
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

Yahoo

time3 hours ago

  • Yahoo

RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 30.9% to a quarterly record of $20.7 million in the second quarter of 2025 from $15.8 million in the second quarter of 2024 Total Company Adjusted EBITDA(1) was a quarterly record of $81.2 million in the second quarter of 2025 as compared with $72.3 million in the second quarter of 2024, an increase of 12.3%; Digital Health reportable segment Adjusted EBITDA(1) increased 4.1% to $3.4 million in the second quarter of 2025 from $3.3 million in the second quarter of 2024 Total Company Adjusted EBITDA(1) margins increased by 57 basis points to 16.3% in the second quarter of 2025 as compared with 15.7% in the second quarter of 2024 As a percentage of total procedural volumes, advanced imaging increased to 27.5% in the second quarter of 2025 from 26.5% in the second quarter of 2024, an increase of 102 basis points Adjusting for unusual or one-time items in the quarter, Adjusted Earnings(3) was $23.8 million and Adjusted Earnings Per Share(3) was $0.31 for the second quarter of 2025; This compares with Adjusted Earnings(3) of $12.0 million and Adjusted Earnings Per Share(3) of $0.16 for the second quarter of 2024 In the second quarter of 2025, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 9.0% and same-center advanced imaging procedural volumes increased 6.6% as compared with the second quarter of 2024 As of June 30, 2025, balance sheet cash was $833.2 million and Net Debt to Adjusted EBITDA(1) ratio was 0.96x RadNet revises full-year 2025 guidance levels to increase Revenue and Adjusted EBITDA(1) guidance ranges LOS ANGELES, Aug. 10, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 405 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2025. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, 'Both the Imaging Center and Digital Health reportable operating segments demonstrated strong growth and achieved record quarterly results. In the second quarter of 2025, total Company Revenue grew 8.4% and Digital Health segment Revenue increased 30.9% from last year's same quarter. Growth was driven by strong increases in aggregate and same center procedural volumes, improved reimbursement from commercial and capitated payors, a continuing shift in procedural volumes towards advanced imaging modalities and incremental Digital Health sales and licenses of workflow software and AI solutions.' Dr. Berger continued, 'Our focus has been on driving more advanced imaging procedures (MRI, CT and PET/CT) and increasing advanced imaging capacity at the imaging centers through a variety of initiatives. Within MRI, the 9.0% aggregate and 6.6% same center growth in the second quarter as compared with last year's second quarter is partially the result of capacity created from investments made in MRI software upgrades and operating protocols which enable shorter scan times. CT programs have expanded on both coasts to offer more complex procedures, such as Cardiac CT Angiography, which is often enhanced with AI-assisted analytics. Within PET/CT, our fastest growing modality with 22.4% growth from last year's second quarter, emphasis has been on newer diagnostic and screening offerings for prostate cancer, Alzheimer's disease and dementia and new procedures with leading-edge tumor-specific radioactive tracers. The growth in advanced imaging, particularly MRI, has been furthered by the implementation of Digital Health's TechLiveTM, our remote screening technology recently cleared by the FDA. TechLiveTM is assisting with ongoing technologist staffing challenges by enabling remote control of advanced imaging equipment to expand hours of operation and by staffing exam rooms which otherwise would have been closed.' 'The growth in advanced imaging from these initiatives along with effective cost management contributed to an increase in our Adjusted EBITDA(1) margin to 16.3% during the second quarter of 2025, which compares with 15.7% in last year's second quarter, an improvement of 57 basis points. Adjusted EBITDA(1) during the second quarter of 2025 increased by 12.3% to $81.2 million from $72.3 million in last year's second quarter,' added Dr. Berger. Dr. Berger continued, 'In response to high demand and patient backlogs in many of RadNet's local markets, we continue to pursue capacity expansion through the development and construction of new imaging centers. One new facility was opened during the second quarter in East Brunswick, New Jersey, and nine additional de novo facility openings are projected for the remainder of 2025. Within Digital Health, we continue to see growth from the nationwide expansion of the AI-powered Enhanced Breast Cancer Detection program, where today almost 45% of RadNet screening mammography patients are electing to participate for a $40 out-of-pocket charge. We continue to make progress with the internal RadNet implementation of the TechLiveTM remote scanning solution, elements of the DeepHealth Operations and Diagnostic suites and the newly acquired See-Mode ultrasound AI capabilities.' 'Given the sustainable positive trends we are experiencing and the strong financial performance of the second quarter, we are revising upwards 2025 guidance levels for Revenue and Adjusted EBITDA(1) in anticipation of financial results that we believe will exceed both our original expectations and the amendments we made to the guidance ranges upon releasing first quarter 2025 results in May,' concluded Dr. Berger. Second Quarter Financial Results For the second quarter of 2025, RadNet reported Total Company Revenue of $498.2 million and Adjusted EBITDA(1) of $81.2 million. Revenue increased $38.5 million (or 8.4%) and Adjusted EBITDA(1) increased $8.9 million (or 12.3%) as compared with the second quarter of 2024. For the second quarter of 2025, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $20.7 million and Adjusted EBITDA(1) of $3.4 million. Revenue increased $4.9 million (or 30.9%) and Adjusted EBITDA(1) increased $134,000 (or 4.1%) as compared with the second quarter of 2024. Unadjusted for unusual or one-time items impacting the second quarter of 2025, Total Company Net Income for the second quarter of 2025 was $14.5 million as compared with a Total Company Net Loss of $3.0 million for the second quarter of 2024. Net Income Per Share for the second quarter of 2025 was $0.19, compared with a Net Loss per share of $(0.04) in the second quarter of 2024, based upon a weighted average number of diluted shares outstanding of 75.5 million shares in 2025 and 73.4 million shares in 2024. There were a number of unusual or one-time items impacting the second quarter including: $2.0 million of non-cash loss from interest rate swaps; $496,000 expense related to leases for de novo facilities under construction that have yet to open their operations; $123,000 of lease abandonment charge; $2.3 million of acquisition transaction costs; and $4.8 million of non-capitalized research and development expenses related to the DeepHealth Cloud OS and generative AI. Adjusting for the above items, Total Company Adjusted Earnings(3) was $23.8 million and diluted Adjusted Earnings Per Share(3) was $0.31 during the second quarter of 2025. This compares with Total Company Adjusted Earnings(3) of $12.0 million and diluted Adjusted Earnings Per Share(3) of $0.16 during the second quarter of 2024. For the second quarter of 2025, as compared with the prior year's second quarter, MRI volume increased 9.0%, CT volume increased 8.1%, PET/CT volume increased 22.4% and routine imaging (inclusive of nuclear medicine, ultrasound, mammography, x-ray and other exams) increased 3.5% over the prior year's second quarter. On a same-center basis, including only those centers which were part of RadNet for both the second quarters of 2025 and 2024, MRI volume increased 6.6%, CT volume increased 5.9%, PET/CT volume increased 16.2% and routine imaging increased 1.4% over the prior year's second quarter. Six Month Financial Results For the first six months of 2025, RadNet reported Total Company Revenue of $969.6 million and Adjusted EBITDA(1) of $127.6 million. Revenue increased $78.2 million (or 8.8%) and Adjusted EBITDA(1) decreased $3.1 million (or 2.4%) as compared with the first six months of 2024. The decrease in Adjusted EBITDA(1) was primarily the result of the previously estimated loss of $15 million of Adjusted EBITDA(1) as a result of the California wildfires and severe winter weather conditions impacting the first quarter of 2025. For the first six months of 2025, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $39.9 million and Adjusted EBITDA(1) of $7.1 million. Revenue increased $9.5 million (or 31.0%) and Adjusted EBITDA(1) increased $325,000 (or 4.8%) as compared with the first six months of 2024. Unadjusted for one-time or unusual items, Total Company Net Loss for the first six months of 2025 was $23.5 million as compared with a Total Company Net Loss of $5.8 million for the first six months of 2024. Net Loss Per Share for the six-month period of 2025 was $(0.32), compared with a Net Loss per share of $(0.08) in the six-month period of 2024, based upon a weighted average number of diluted shares outstanding of 74.1 million shares in 2025 and 71.8 million shares in 2024. 2025 Guidance Update RadNet updates guidance levels as follows: Imaging Center Segment Original Guidance Range Revised Guidance Range After Q1 Results Revised Guidance Range After Q2 Results Total Net Revenue $1,825 - $1,875 million $1,835 - $1,885 million $1,850 - $1,900 million Adjusted EBITDA(1) $265 - $273 million $268 - $276 million $271 - $279 million Capital Expenditures(a) $140 - $150 million $145 - $155 million $152 - $162 million Cash Interest Expense(b) $35 - $40 million $35 - $40 million $35 - $40 million Free Cash Flow (2) $70 - $80 million $70 - $80 million $70 - $80 million (a) Net of proceeds from the sale of equipment and New Jersey Imaging Network capital expenditures. (b) Net of payments from counterparties on interest rate swaps and interest income from our cash balance recorded in Other Health Segment OriginalGuidance Range RevisedGuidance Range AfterQ1 Results RevisedGuidance Range AfterQ2 Results Total Net Revenue (inclusive of intersegment revenue) $80 - $90 million $80 - $90 million $80 - $90 million Adjusted EBITDA(1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI $15 - $17 million $15 - $17 million $15 - $17 million Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI $16 - $18 million $16 - $18 million $17 - $19 million Capital Expenditures $3 - $5 million $3 - $5 million $2 - $4 million Free Cash Flow(2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI $11 - $13 million $11 - $13 million $11 - $13 million Free Cash Flow(2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI $(5) - $(8) million $(5) - $(8) million $(5) - $(8) million Conference Call for Tomorrow Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its second quarter 2025 results on Monday, August 11th, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Conference Call Details: Date: Monday, August 11, 2025Time: 10:30 a.m. Eastern TimeDial In-Number: 844-826-3035International Dial-In Number: 412-317-5195 It is recommended that participants dial in approximately 5 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at or under the 'Investors' menu section and 'News Releases' sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 405 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 team members. For more information, visit press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods. Forward-looking statements in this press release include, among others, statements about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to service or refinance our current indebtedness. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the availability and terms of capital to fund our business; our ability to service our indebtedness, make principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms; changes in general economic conditions nationally and regionally in the markets in which we operate; the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities; our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so; our ability to acquire, develop, implement and monetize technology, digital health initiatives, artificial intelligence algorithms and applications; volatility in interest and exchange rates, or credit markets; the adequacy of our cash flow and earnings to fund our current and future operations; changes in service mix, revenue mix and procedure volumes; delays in receiving payments for services provided; increased bankruptcies among our partner physicians or joint venture partners; the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act; the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business; closures or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in our facilities; the occurrence of hostilities, political instability or catastrophic events; the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; and noncompliance by us with any privacy or security laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information. Any forward-looking statement contained in this current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow. RADNET, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA) June 30, 2025 December 31, 2024 (unaudited) ASSETS CURRENT ASSETS Cash and Cash equivalents $ 833,152 $ 740,020 Accounts receivable 199,991 185,821 Due from affiliates 12,959 41,869 Prepaid expenses and other current assets 48,277 51,542 Total current assets 1,094,379 1,019,252 PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS Property and equipment, net 741,382 694,791 Operating lease right-of-use assets 666,054 639,740 Total property, plant, equipment and right-of-use assets 1,407,436 1,334,531 OTHER ASSETS Goodwill 751,514 710,663 Other intangible assets 91,078 81,351 Deferred financing costs 1,974 2,265 Investment in joint ventures 125,804 104,057 Deposits and other 42,781 34,571 Total Assets $ 3,514,966 $ 3,286,690 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable, accrued expenses and other $ 406,689 $ 351,464 Due to affiliates 51,067 43,650 Deferred revenue 3,433 3,288 Current operating lease liability 59,537 56,618 Current portion of notes payable 25,484 24,692 Total current liabilities 546,210 479,712 LONG-TERM LIABILITIES Long-term operating lease liability 678,783 655,979 Notes payable, net of current portion 1,077,251 991,574 Deferred tax liability, net 21,441 22,230 Other non-current liabilities 12,020 3,785 Total liabilities 2,335,705 2,153,280 EQUITY RadNet, Inc. stockholders' equity: Common stock - $0.0001 value, 200,000,000 shares authorized; 75,067,102 and 74,036,993 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 8 7 Additional paid-in-capital 1,025,936 988,147 Accumulated other comprehensive loss 6,627 (9,061 ) Accumulated deficit (100,257 ) (76,785 ) Total RadNet, Inc.'s Stockholders' equity: 932,314 902,308 Noncontrolling interests 246,947 231,102 Total Equity 1,179,261 1,133,410 Total liabilities and equity $ 3,514,966 $ 3,286,690 RADNET, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUE Service fee revenue $ 468,063 $ 422,745 $ 907,412 $ 819,934 Revenue under capitation arrangements 30,167 36,969 62,217 71,487 Total service revenue 498,230 459,714 969,629 891,421 OPERATING EXPENSES Cost of operations, excluding depreciation and amortization 429,085 389,724 882,565 777,313 Lease abandonment charges 123 - 5,511 - Depreciation and amortization 35,993 34,475 71,476 66,843 Loss (gain) on sale and disposal of equipment and other 1,724 401 2,126 587 Severance costs 426 268 1,173 493 Total operating expenses 467,351 424,868 962,851 845,236 INCOME (LOSS) FROM OPERATIONS 30,879 34,846 6,778 46,185 OTHER INCOME AND EXPENSES Interest expense 17,189 26,082 34,428 42,349 Equity in earnings of joint ventures (4,356 ) (3,389 ) (6,955 ) (7,713 ) Non-cash change in fair value of interest rate hedge 1,956 1,890 4,062 674 Debt restructuring and extinguishment expenses - 8,762 - 8,762 Other (income) expenses (7,764 ) (7,900 ) (15,476 ) (10,834 ) Total other (income) expenses 7,025 25,445 16,059 33,238 INCOME (LOSS) BEFORE INCOME TAXES 23,854 9,401 (9,281 ) 12,947 Provision for income taxes (820 ) (2,456 ) 2,578 (592 ) NET INCOME (LOSS) 23,034 6,945 (6,703 ) 12,355 Net income (loss) attributable to noncontrolling interests 8,580 9,927 16,769 18,116 NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 14,454 $ (2,982 ) $ (23,472 ) $ (5,761 ) BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 0.19 $ (0.04 ) $ (0.32 ) $ (0.08 ) DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 0.19 $ (0.04 ) $ (0.32 ) $ (0.08 ) WEIGHTED AVERAGE SHARES OUTSTANDING Basic 74,352,498 73,419,124 74,070,438 71,795,080 Diluted 75,531,743 73,419,124 74,070,438 71,795,080 RADNET, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS (IN THOUSANDS) (unaudited) Six Months Ended June 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net (loss) income $ (6,703 ) $ 12,355 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and amortization 71,476 66,843 Noncash operating lease expense 29,356 30,006 Equity in earnings of joint ventures, net of dividends (1,267 ) (6,713 ) Amortization of deferred financing costs and loan discount 1,471 1,541 Loss on sale and disposal of equipment 2,126 587 Loss on extinguishment of debt - 2,080 Lease abandonment charges 5,511 - Amortization of cash flow hedge 2,712 7,256 Non-cash change in fair value of interest rate swap 4,062 674 Stock-based compensation 37,235 16,645 Change in fair value of contingent consideration - 1,974 Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Accounts receivable (14,159 ) (31,581 ) Other current assets 22,381 5,242 Other assets (2,544 ) (5,553 ) Deferred taxes (3,511 ) 1,791 Operating leases (34,726 ) (27,707 ) Deferred revenue 145 (185 ) Accounts payable, accrued expenses and other 48,264 57,835 Net cash provided by operating activities 161,829 133,090 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of imaging facilities and other acquisitions, net of cash acquired (31,985 ) (32,771 ) Purchase of property and equipment and other (101,776 ) (104,095 ) Proceeds from sale of equipment 40 9 Equity contributions in existing and purchase of interest in joint ventures (20,480 ) (1,421 ) Net cash used in investing activities (154,201 ) (138,278 ) CASH FLOWS FROM FINANCING ACTIVITIES Principal payments on notes and leases payable (3,461 ) (2,624 ) Payments on Term Loan Debt (10,252 ) (682,438 ) Proceeds from issuance of new debt, net of issuing costs 99,001 863,869 Purchase of noncontrolling interests by third party 2,389 4,169 Payments on contingent consideration and holdbacks - (3,614 ) Distributions paid to noncontrolling interests (3,313 ) (2,423 ) Proceeds from sale of economic interests in majority owned subsidiary, net of taxes - 8,713 Proceeds from issuance of common stock - 218,385 Proceeds from issuance of common stock upon exercise of options 554 367 Net cash provided by financing activities 84,918 404,404 EFFECT OF EXCHANGE RATE CHANGES ON CASH 586 (107 ) NET INCREASE IN CASH AND CASH EQUIVALENTS 93,132 399,109 CASH AND CASH EQUIVALENTS, beginning of period 740,020 342,570 CASH AND CASH EQUIVALENTS, end of period 833,152 741,679 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid during the period for interest $ 35,018 $ 34,203 Cash paid during the period for income taxes $ 2,428 $ 705 RADNET, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA (IN THOUSANDS) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net income (loss) attributable to Radnet, Inc. common stockholders $ 14,454 $ (2,982 ) $ (23,472 ) $ (5,761 ) Income taxes 820 2,456 (2,578 ) 592 Interest expense 17,189 26,082 34,428 42,349 Severance costs 426 268 1,173 493 Depreciation and amortization 35,993 34,475 71,476 66,843 Non-cash employee stock-based compensation 8,741 4,749 37,235 16,646 Loss (gain) on sale and disposal of equipment and other 1,724 401 2,126 587 Non-cash change in fair value of interest rate hedge 1,956 1,890 4,062 674 Other expenses (income) (7,764 ) (7,900 ) (15,476 ) (10,834 ) Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 4,787 3,317 8,349 6,632 Lease abandonment charges 123 - 5,511 - Loss (gain) on extinguishment of debt and related expenses - 8,762 - 8,762 Non-cash change to contingent consideration - - - 1,974 Non-operational rent expenses 496 809 1,838 1,832 Acquisition transaction costs 2,301 - 2,973 - Adjusted EBITDA - Radnet, Inc. $ 81,246 $ 72,327 $ 127,645 $ 130,789 NOTE Adjusted EBITDA - Imaging Center Segment 77,843 69,058 120,531 124,000 Adjusted EBITDA - Digital Health Segment 3,403 3,269 7,114 6,789 PAYMENTS BY PAYOR CLASS Second Quarter 2025 Commercial Insurance 58.3% Medicare 23.3% Capitation 6.1% Medicaid 2.5% Workers Compensation/Personal Injury 2.1% Other* 7.6% Total 100.0% * Includes Management Fees, Digital Health Revenue and Heart Lung Health Revenue. RADNET PAYMENTS BY MODALITY Second Quarter Full Year Full Year Full Year 2025 2024 2023 2022 MRI 37.3 % 37.1 % 36.8 % 36.8 % CT 15.7 % 15.9 % 16.8 % 17.5 % PET/CT 8.7 % 7.2 % 6.4 % 5.8 % X-ray 5.6 % 6.0 % 6.5 % 6.7 % Ultrasound 13.6 % 13.6 % 12.9 % 12.6 % Mammography 15.8 % 16.4 % 16.0 % 15.3 % Nuclear Medicine 0.9 % 1.0 % 0.8 % 0.9 % Other 2.5 % 2.7 % 3.9 % 4.5 % 100.0 % 100.0 % 100.0 % 100.0 % PROCEDURES BY MODALITY* Second Quarter Second Quarter 2025 2024 MRI 490,299 449,781 CT 291,820 269,939 PET/CT 22,155 18,107 Nuclear Medicine 9,377 9,610 Ultrasound 701,917 664,043 Mammography 508,000 483,510 X-ray and Other 900,095 890,814 Total 2,923,663 2,785,804 * Volumes include wholy owned and joint venture centers. RADNET, INC. AND SUBSIDIARIES SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE (3) (IN THOUSANDS EXCEPT SHARE DATA) (unaudited) Three Months Ended June 30, 2025 2024 NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 14,454 $ (2,982 ) Add/Subtract non-cash change in fair value of interest rate swaps (i) 1,956 1,890 Non-cash interest expense from extraordinary interest rate swap OCI amortization - 5,559 Non-operational rent expenses (iii) 496 809 Contingent consideration - - Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 4,787 3,317 Lease abandonment charge 123 - Acquisition transaction costs 2,301 - Debt restructing and extinguishment expenses (iv) - 8,762 Total adjustments - loss (gain) 9,663 20,337 Subtract tax impact of Adjustments (ii) (332 ) (5,308 ) Tax effected impact of adjustments 9,331 15,029 TOTAL ADJUSTMENT TO NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS 9,331 15,029 ADJUSTED NET INCOME ATTRIBUTABLE TO RADNET, INC. 23,785 12,047 COMMON STOCKHOLDERS WEIGHTED AVERAGE SHARES OUTSTANDING Diluted 75,531,743 74,944,366 ADJUSTED DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 0.31 $ 0.16 (i) Impact from the change in fair value of the swaps during the quarter. Excludes the recurring amortization of the accumulation of the changes in fair value out of Other Comprehensive Income that existed prior to the hedges becoming ineffective. (ii) Tax effected using 3.44% and 26.10% blended federal and state effective tax rate for the second quarter of 2025 and 2024, respectively. (iii) Represents rent expense associated with de novo sites under construction prior to them becoming operational. (iv) Extraordinary expense related to the Company's successful April 2024 debt refinancing transaction. Footnotes (1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period. Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies. (2) As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest Expense. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies. Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies. (3) The Company defines Adjusted Earnings (Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation, gain on extinguishment of debt, unusual or non-recurring entries that impact the Company's tax provision and any other non-recurring or unusual transactions recorded during the period. Adjusted Earnings (Loss) Per Share is reconciled to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other in to access your portfolio

‘Active' Mom of 2 Had No Symptoms Before Sudden ‘Agonizing Pain' in Her Chest Led to Shocking Diagnosis
‘Active' Mom of 2 Had No Symptoms Before Sudden ‘Agonizing Pain' in Her Chest Led to Shocking Diagnosis

Yahoo

time4 hours ago

  • Yahoo

‘Active' Mom of 2 Had No Symptoms Before Sudden ‘Agonizing Pain' in Her Chest Led to Shocking Diagnosis

Sharon Smith's leukemia diagnosis came as a "complete shock" after rushing to the emergency room with chest painNEED TO KNOW Sharon Smith, from Liverpool, England, was diagnosed with an acute form of leukemia after experiencing chest pain The mom of 2 said the diagnosis came as a "complete shock" as she had "no symptoms" before returning from vacation "I'd been playing football in the garden with my little grandson the night before I got this pain," Smith said in Clatterbridge Cancer Centre's news releaseA woman in England had "no symptoms at all" before a sudden pain in her chest led to a devastating diagnosis. Sharon Smith, from Liverpool, went to a local emergency room after she began to experience "an agonizing pain in her chest" in April 2023, according to a news release shared by the city's Clatterbridge Cancer Centre, which is where she was initially treated. Following blood tests and a bone marrow biopsy, the mother of two was diagnosed with acute lymphoblastic leukemia (ALL). "It came as a complete shock," Smith said, per the news release. Acute lymphocytic leukemia — also known as acute lymphoblastic leukemia — "is a type of cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made," according to the Mayo Clinic. "The word 'acute' in acute lymphocytic leukemia comes from the fact that the disease progresses rapidly and creates immature blood cells, rather than mature ones," the organization states. Smith — who lives with her husband, Paul, and has two sons and a grandson — said she had "no symptoms at all" before the shocking cancer diagnosis. "We'd just come back from [vacation] where I'd walked the length of Spain and I'd been playing football in the garden with my little grandson the night before I got this pain," she recalled, per the Clatterbridge Cancer Centre's news release. Smith was sent to the Clatterbridge Cancer Centre for chemotherapy following the diagnosis. In November 2023, she then underwent a "stem cell transplant from a donor to help her create healthy new blood cells and reduce the risk of the cancer returning," according to the news release. 'I felt really good after the stem cell transplant,' Smith said. 'I've always been on the go, really active and busy, and I felt like my usual self again." 'I was still coming for regular check-ups at Clatterbridge and, in September 2024, my routine bone marrow biopsy showed I had relapsed and the cancer was back. I just wasn't expecting it so, as you can imagine, I was completely shocked," she continued. 'That was a Tuesday and I went home thinking this was the end for me, then on the Friday I got a lovely phone call from the consultant, Dr. Saif, to say he'd been working behind the scenes to try and find another treatment for me and I'd been accepted for CAR-T therapy," she added, referencing the chimeric antigen receptor T cell therapy, which is a highly innovative form of immunotherapy, per the hospital. According to the American Cancer Society, CAR-T therapy "is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells." "This type of treatment can be very helpful in treating some types of cancer, even when other treatments are no longer working," according to the society. Speaking about being accepted for the treatment, Smith said, 'I went from literally the worst time in life to feeling like I'd just won the lottery because there was a little bit of hope there," per the news release. Due to CAR-T therapy not being available in Liverpool until the end of 2024, Smith was referred to The Christie in Manchester for her to receive treatment as soon as possible. She said the approximately 34-mile journey to Manchester was "exhausting," adding, "We were over and back about 20 times in all for consultations, cell collection, chemotherapy, infusion and follow-up appointments afterwards." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. Smith also had to stay in the city for three and a half weeks "during the most intensive stage of treatment." Having gone to Manchester to have T cells taken from her blood, Smith's cells were then taken to a specialist pharmaceutical laboratory to be transformed into a "unique" CAR-T treatment. She then had to undergo chemotherapy in Manchester to prepare her body before the treatment began. Despite some side effects, the treatment was successful and Smith "recovered quickly," according to the hospital's news release. "Her bone marrow biopsies and blood tests are looking good and she is hopeful for what the future will bring," per the news release. Read the original article on People Solve the daily Crossword

7-Day Antioxidant-Rich Meal Plan for Weight Loss, Created by a Dietitian
7-Day Antioxidant-Rich Meal Plan for Weight Loss, Created by a Dietitian

Yahoo

time5 hours ago

  • Yahoo

7-Day Antioxidant-Rich Meal Plan for Weight Loss, Created by a Dietitian

Reviewed by Dietitian Jessica Ball, M.S., RDAbout This Plan ● This 7-day plan is set at 1,500 calories, with modifications for 1,800 and 2,000 calories ● Each day provides at least 60 grams of protein and 30 grams of fiber to promote satiety and digestive health. ● This plan prioritizes antioxidant-rich foods to support weight you're looking to support your weight-loss goals, antioxidants deserve a spot on your plate. These powerful compounds, found in fruits, vegetables, legumes, nuts and whole grains, have been linked to improved weight loss outcomes. By following this 7-day meal plan, you'll enjoy satisfying and nutrient-rich meals and snacks that highlight these plant-derived nutrients without sacrificing flavor. Berries, leafy greens, tomatoes, carrots, beans and herbs are just a few of the standout foods included in this plan. Whether your goal is to lose weight or incorporate more plants into your diet, this week-long meal plan offers a practical and delicious way to enhance your health. Meal Plan at a Glance Baked eggs & veggies/ Apple & nut butter Bean salad/ Pistachios Chicken hummus bowls Smoothie bowl/ Energy balls Chicken salad/ Mini stuffed peppers Shrimp pesto bowls Smoothie bowl/ Energy balls Chicken salad/ Mini stuffed peppers Salmon, rice & bok choy Smoothie bowl/ Energy balls Chicken salad/ Mini stuffed peppers Chicken guacamole bowl Smoothie bowl/ Energy balls Chicken salad/ Mini stuffed peppers White bean skillet Overnight oats/ Yogurt & berries Tuna salad/ Snack jar Italian wedding soup Overnight oats/ Yogurt & berries Tuna salad/ Snack jar Tofu tostadas Day 1 Breakfast (344 Calories) ● 1 serving Baked Eggs in Tomato Sauce with Kale Morning Snack (173 Calories) ● 1 small apple ● 1 tablespoon unsalted peanut butter Lunch (322 calories) ● 1 serving No-Cook Black Bean Salad Afternoon Snack (183 Calories) ● ¼ cup pistachios Dinner (485 Calories) ● 1 serving Chicken Hummus Bowls Daily totals: 1,508 calories, 88 g fat, 74 g protein, 122 g carbohydrates, 36 g fiber, 1,778 mg sodium To make it 1,800 calories: Add 1 serving Berry-Kefir Smoothie to afternoon snack. To make it 2,000 calories: Add 1 serving Berry-Kefir Smoothie to afternoon snack. Add 2 servings Blueberry-Pecan Energy Balls as an evening snack. Day 2 Breakfast (352 Calories) ● 1 serving Raspberry-Peach-Mango Smoothie Bowl Morning Snack (153 Calories) ● 1 serving Blueberry-Pecan Energy Balls ● ½ pear Lunch (410 calories) ● 1 serving Spinach Salad with Quinoa, Chicken & Fresh Berries Afternoon Snack (157 Calories) ● 1 serving White Bean–Stuffed Mini Bell Peppers ● 1 clementine Dinner (429 Calories) ● 1 serving Charred Shrimp, Pesto & Quinoa Bowls Daily totals: 1,502 calories, 65 g fat, 85 g protein, 155 g carbohydrates, 33 g fiber, 1,650 mg sodium To make it 1,800 calories: Change 1 clementine to 2 clementines in afternoon snack. Add 1 serving of Crunchy High-Protein Quinoa Bites as an evening snack. To make it 2,000 calories: Change morning snack to 3 servings of Blueberry-Pecan Energy Balls. Change 1 clementine to 2 clementines in afternoon snack. Add 1 serving of Crunchy High-Protein Quinoa Bites as an evening snack. Day 3 Breakfast (352 Calories) ● 1 serving Raspberry-Peach-Mango Smoothie Bowl Morning Snack (153 Calories) ● 1 serving Blueberry-Pecan Energy Balls ● ½ pear Lunch (410 calories) ● 1 serving Spinach Salad with Quinoa, Chicken & Fresh Berries Afternoon Snack (154 Calories) ● 1 serving White Bean–Stuffed Mini Bell Peppers ● ½ cup raspberries Dinner (421 Calories) ● 1 serving Sheet-Pan Salmon with Bok Choy & Rice Daily totals: 1,491 calories, 61 g fat, 88 g protein, 155 g carbohydrates, 31 g fiber, 1,803 mg sodium To make it 1,800 calories: Change ½ cup raspberries to 1 cup raspberries in afternoon snack. Add 1 serving of Crunchy High-Protein Quinoa Bites as an evening snack. To make it 2,000 calories: Change morning snack to 3 servings of Blueberry-Pecan Energy Balls. Change ½ cup raspberries to 1 cup raspberries in afternoon snack. Add 1 serving of Crunchy High-Protein Quinoa Bites as an evening snack. Day 4 Breakfast (352 Calories) ● 1 serving Raspberry-Peach-Mango Smoothie Bowl Morning Snack (153 Calories) ● 1 serving Blueberry-Pecan Energy Balls ● ½ pear Lunch (410 calories) ● 1 serving Spinach Salad with Quinoa, Chicken & Fresh Berries Afternoon Snack (157 Calories) ● 1 serving White Bean–Stuffed Mini Bell Peppers ● 1 clementine Dinner (453 Calories) ● 1 serving Chicken Guacamole Bowls Deliver 32 Grams of Protein Daily totals: 1,526 calories, 72 g fat, 86 g protein, 148 g carbohydrates, 35 g fiber, 1,877 mg sodium To make it 1,800 calories: Add 1 serving of Crunchy High-Protein Quinoa Bites as an evening snack. To make it 2,000 calories: Change morning snack to 3 servings of Blueberry-Pecan Energy Balls. Add 1 serving of Crunchy High-Protein Quinoa Bites as an evening snack. Day 5 Breakfast (352 Calories) ● 1 serving Raspberry-Peach-Mango Smoothie Bowl Morning Snack (153 Calories) ● 1 serving Blueberry-Pecan Energy Balls ● ½ pear Lunch (410 calories) ● 1 serving Spinach Salad with Quinoa, Chicken & Fresh Berries Afternoon Snack (122 Calories) ● 1 serving White Bean–Stuffed Mini Bell Peppers Dinner (458 Calories) ● 1 serving One-Pot White Bean, Spinach & Sun-Dried Tomato Orzo with Lemon & Feta Daily totals: 1,496 calories, 53 g fat, 75 g protein, 191 g carbohydrates, 39 g fiber, 1,752 mg sodium To make it 1,800 calories: Add 1 serving of Crunchy High-Protein Quinoa Bites as an evening snack. Add 1 clementine to afternoon snack. To make it 2,000 calories: Change morning snack to 3 servings of Blueberry-Pecan Energy Balls. Add 1 clementine to afternoon snack. Add 1 serving of Crunchy High-Protein Quinoa Bites as an evening snack. Day 6 Breakfast (407 Calories) ● 1 serving Berry Crumble Overnight Oats Morning Snack (182 Calories) ● ½ cup whole milk strained-style (such as Greek) yogurt ● 1 cup blackberries Lunch (304 calories) ● 1 serving Chickpea Tuna Salad Afternoon Snack (168 Calories) ● 1 serving High-Fiber Guacamole Snack Jar Dinner (415 Calories) ● 1 serving Italian Wedding Soup Daily totals: 1,476 calories, 66 g fat, 79 g protein, 147 g carbohydrates, 32 g fiber, 1,791 mg sodium To make it 1,800 calories: Add 1 serving Berry-Kefir Smoothie as an evening snack To make it 2,000 calories: Change ½ cup yogurt to 1 cup yogurt in morning snack and add 2 tablespoons chia seeds. Add 1 serving Berry-Kefir Smoothie as an evening snack. Day 7 Breakfast (407 Calories) ● 1 serving Berry Crumble Overnight Oats Morning Snack (182 Calories) ● ½ cup whole milk strained-style (such as Greek) yogurt ● 1 cup blackberries Lunch (304 calories) ● 1 serving Chickpea Tuna Salad Afternoon Snack (168 Calories) ● 1 serving High-Fiber Guacamole Snack Jar Dinner (432 Calories) ● 1 serving Cajun-Spiced Tofu Tostadas with Beet Crema Daily totals: 1,493 calories, 72 g fat, 69 g protein, 152 g carbohydrates, 38 g fiber, 1,793 mg sodium To make it 1,800 calories: Add 1 serving Berry-Kefir Smoothie as an evening snack To make it 2,000 calories: Change ½ cup yogurt to 1 cup yogurt in morning snack and add 2 tablespoons chia seeds. Add 1 serving Berry-Kefir Smoothie as an evening Ahead Tips Prepare Blueberry-Pecan Energy Balls to have for morning snack on Days 2 through 5. Make Spinach Salad with Quinoa, Chicken & Fresh Berries to have for lunch on Days 2 through 5. Prepare White Bean–Stuffed Mini Bell Peppers to have as an afternoon snack on Days 2 through 5. Make Berry Crumble Overnight Oats to have for breakfast on Days 6 and asked Questions Is it OK to mix and match meals if there's one I don't like? Yes! This meal plan is meant to serve as inspiration. It doesn't need to be followed exactly to reap the benefits. When choosing recipes, we made sure to check the calories, fiber, protein and sodium to align with the parameters of this plan and be within our sodium limits. If you're making a recipe swap, it may be helpful to choose a recipe with similar calories, fiber, protein and sodium levels. For more inspiration, check out these delicious Recipes for Weight Loss. Can I eat the same breakfast or lunch every day? Definitely, it's fine to eat the same breakfast or lunch every day. The breakfasts range from 350 to 400 calories while the lunches span 350 to 400 calories. These ranges are fairly close, though if you're closely monitoring your calories or other nutrients, like protein, you may want to adjust a snack or two. Why is there not a 1,200 calorie modification? We no longer provide modifications for 1,200-calorie days in our meal plans. The 2020-2025 Dietary Guidelines for Americans suggests that limiting calories to 1,200 per day is too low for most people to meet their nutritional needs, plus it's unsustainable for long-term health and well-being. Health Benefits of Antioxidants for Weight Loss Hidden within the vibrant colors of plant foods are powerful antioxidants that can support your weight loss efforts in more ways than one. Antioxidants, such as vitamin C, vitamin E, beta-carotene, polyphenols and selenium, are well-known for their role in protecting your cells from harmful molecules called free radicals. When free radicals are left unchecked, they create oxidative stress—a kind of internal chaos that is associated with the development and progression of inflammation and obesity. This is where antioxidants come into play, helping to neutralize these unruly molecules and prevent oxidative damage. In doing so, antioxidants can help reduce inflammation, regulate cellular processes involved in energy metabolism and adipose (fat) tissue function. They have also been shown to improve appetite control and insulin sensitivity, which are key factors in maintaining a healthy weight. As a result, incorporating the antioxidant-rich foods in this meal plan can be a smart and sustainable way to support your long-term weight loss goals and improve your overall We Create Meal Plans Registered dietitians thoughtfully create EatingWell's meal plans to be easy-to-follow and delicious. Each meal plan meets specific parameters depending on the health condition and/or lifestyle goal it is targeting and is analyzed for accuracy using the nutrition database, ESHA Food Processor. As nutritional needs differ from person to person, we encourage you to use these plans as inspiration and adjust as you see the original article on EATINGWELL

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store